Navigation Links
Micromet, Inc. to Host Conference Call and Webcast to Discuss Second Quarter 2008 Financial Results
Date:7/29/2008

se 1 clinical trial for the treatment of patients with non-Hodgkin's lymphoma. BiTE antibodies represent a new class of antibodies that activate the T cells of a patient's own immune system, to eliminate cancer cells. Micromet is developing blinatumomab in collaboration with MedImmune, Inc., a subsidiary of AstraZeneca plc. MT110 is the second BiTE antibody in clinical trials, and is being developed by Micromet in a phase 1 clinical trial for the treatment of patients with lung or gastrointestinal cancer. The third clinical stage antibody is adecatumumab, also known as MT201, a human monoclonal antibody which targets epithelial cell adhesion molecule (EpCAM)-expressing solid tumors. Micromet is developing adecatumumab in collaboration with Merck Serono in a phase 1b clinical trial evaluating adecatumumab in combination with docetaxel for the treatment of patients with metastatic breast cancer. The fourth clinical stage antibody is MT293, which is licensed to TRACON Pharmaceuticals, Inc. and is being developed in a phase 1 clinical trial for the treatment of patients with cancer. Three additional BiTE antibodies, targeting CD33, CEA and MCSP, are in preclinical development. In addition, Micromet has established a collaboration with Nycomed for the development and commercialization of MT203, a human antibody neutralizing the activity of granulocyte/macrophage colony stimulating factor (GM-CSF), which has potential applications in the treatment of various inflammatory and autoimmune diseases, such as rheumatoid arthritis, psoriasis, or multiple sclerosis.

Forward-Looking Statements

This release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Factors that may cause actual results to differ materially from any future results expressed or implied by any forward-
'/>"/>

SOURCE Micromet, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
2. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
3. Pre-clinical Data on Recent Advances with HIV VLP Vaccine Presented at AIDS Vaccine 07 Conference
4. Poniard Pharmaceuticals to Present Updated Results of Picoplatin Phase 2 Small Cell Lung Cancer Trial at 12th World Conference on Lung Cancer
5. ViroPharma to Present at Three Upcoming Healthcare Conferences
6. Advanced Life Sciences to Present Data on Selected Cethromycin Therapeutic Studies at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
7. Threshold Pharmaceuticals Announces Two Presentations on Glufosfamide at the 2007 European Cancer Conference (ECCO)
8. GeoVax Successful HIV/AIDS Vaccine Trial Data Presented at AIDS Vaccine 2007 Conference
9. Arena Pharmaceuticals to Present at Four Upcoming Investor Conferences
10. Promising Data from Paratek Pharmaceuticals MAR Inhibitor Program Presented in Late Breaker Session at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
11. Alfacell Corporation to Present at UBS Global Life Sciences Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... and MARSEILLE, France , July 24, ... global license from University of Tokyo enables development of ... gene panels, for blood cancers  Mutations of ... favorable prognosis for patients with bone marrow disorders known ... developing companion diagnostics to guide treatment with new anti-cancer ...
(Date:7/24/2014)... 2014  IRIDEX Corporation (NASDAQ: IRIX ) ... 2014 financial results after the market closes on ... release, the Company will host a conference call with ... on Thursday, July 31, 2014 to ... developments. Interested parties may access the live ...
(Date:7/24/2014)... 24, 2014  IGI Laboratories, Inc. (NYSE MKT: IG), a ... announced its financial results for the second quarter ended June ... , Total revenues of $6.5 million in the second quarter ... in 2013 , Total revenues of $13.3 million for ... 78% over the same period in 2013 , Total ...
Breaking Medicine Technology:QIAGEN Adds Promising Genomic Biomarkers for Assessing Prognosis in Treatment of Blood Cancers to Personalized Healthcare Pipeline 2QIAGEN Adds Promising Genomic Biomarkers for Assessing Prognosis in Treatment of Blood Cancers to Personalized Healthcare Pipeline 3QIAGEN Adds Promising Genomic Biomarkers for Assessing Prognosis in Treatment of Blood Cancers to Personalized Healthcare Pipeline 4QIAGEN Adds Promising Genomic Biomarkers for Assessing Prognosis in Treatment of Blood Cancers to Personalized Healthcare Pipeline 5IGI Laboratories Announces Second Quarter 2014 Results 2IGI Laboratories Announces Second Quarter 2014 Results 3IGI Laboratories Announces Second Quarter 2014 Results 4IGI Laboratories Announces Second Quarter 2014 Results 5IGI Laboratories Announces Second Quarter 2014 Results 6IGI Laboratories Announces Second Quarter 2014 Results 7
... Sept. 12, 2011 The National Association of ... that facilitates cooperation between law enforcement, healthcare professionals, ... prevention and investigation of drug diversion – today ... survey by the Substance Abuse and Mental Health ...
... HAYWARD, Calif., Sept. 12, 2011 Intarcia Therapeutics, ... abstracts on ITCA 650 (DUROS® subcutaneous continuous delivery ... diabetes at the 47th Annual Meeting of the ... Lisbon, Portugal.  All three presentations are scheduled for ...
Cached Medicine Technology:Intarcia Announces Presentations of Three Clinical Abstracts at the 47th Annual Meeting of the European Association for the Study of Diabetes 2Intarcia Announces Presentations of Three Clinical Abstracts at the 47th Annual Meeting of the European Association for the Study of Diabetes 3Intarcia Announces Presentations of Three Clinical Abstracts at the 47th Annual Meeting of the European Association for the Study of Diabetes 4
(Date:7/25/2014)... Ireland (PRWEB) July 26, 2014 ... quality legal help to people who have suffered ... the launch of both their new company, and ... article on the new website explained, http://www.personalinjurysolicitorsireland.com/personal-injury-claims ... law. The focus of the company is always ...
(Date:7/25/2014)... CA (PRWEB) July 25, 2014 In recent ... about, and eager to reverse the symptoms associated with age-related ... the media at large, a new case study ... real benefits of testosterone therapy using bioidentical hormones. , ... 38-year-old father from Seattle who found himself beginning to feel ...
(Date:7/25/2014)... 2014 A federal judge has denied ... DePuy Pinnacle hip lawsuits ( http://www.depuypinnacle-lawsuit.com/ ) selected ... to go before a jury on September 1, 2014, ... July 18th, U.S. District Judge Ed Kinkeade of the ... claims may proceed to trial against Johnson & Johnson, ...
(Date:7/25/2014)... York, NY (PRWEB) July 25, 2014 ... ticket prices across the board for the Guinness International ... FC and Olympiacos FC at Soldier Field on ... also offering their customer appreciation promo/coupon/offer code SOCCER-2014 for ... an amazing year for diehard soccer fans in North ...
(Date:7/25/2014)... of America (GSA) the nation,s largest ... has chosen Heather M. Young, PhD, RN, ... the 2014 recipient of the Doris Schwartz Gerontological ... by GSA,s Health Sciences Section, is given to ... outstanding and sustained contribution to gerontological nursing research. ...
Breaking Medicine News(10 mins):Health News:PersonalInjurySolicitorsIreland.com Announces the Launch of their New Company and Website 2Health News:New Case Study Highlights Effectiveness of Testosterone Therapy in Fighting Weight Gain and Fatigue 2Health News:New Case Study Highlights Effectiveness of Testosterone Therapy in Fighting Weight Gain and Fatigue 3Health News:First Federal DePuy Pinnacle Hip Lawsuits Headed for Trial, As Judge Denies Defense Motions For Dismissal, Summary Judgment, Bernstein Liebhard LLP Reports 2Health News:First Federal DePuy Pinnacle Hip Lawsuits Headed for Trial, As Judge Denies Defense Motions For Dismissal, Summary Judgment, Bernstein Liebhard LLP Reports 3Health News:First Federal DePuy Pinnacle Hip Lawsuits Headed for Trial, As Judge Denies Defense Motions For Dismissal, Summary Judgment, Bernstein Liebhard LLP Reports 4Health News:Liverpool FC vs. Olympiacos FC Tickets Soldier Field: Ticket Down Slashes Ticket Prices for Guinness International Champions Cup in Chicago on Sunday, July 27th 2Health News:Young earns GSA's 2014 Doris Schwartz Gerontological Nursing Research Award 2
... HealthDay Reporter , WEDNESDAY, Oct. 5 (HealthDay ... early stage ,breast cancer using Herceptin and chemotherapy, while ... drug known as an anthracycline, improves survival while posing ... tested three different regimens, one of which did not ...
... CHAPEL HILL, N.C. -- Cam Patterson, MD, MBA, division ... at Chapel Hill School of Medicine has been named ... Association Judah Folkman Award in Vascular Biology. The ... at mid-career (within fifteen years of their first faculty ...
... HealthDay Reporter , WEDNESDAY, Oct. 5 (HealthDay ... can safely undergo MRIs to screen for cancer and ... a new study finds. Those procedures include only ... or later or defibrillators manufactured in 2000 or later, ...
... By Jenifer Goodwin HealthDay Reporter , WEDNESDAY, ... mice whose symptoms closely mimic autism in humans. ... the mice in this study come closer to mirroring ... in humans, said senior study author Matthew Anderson, an ...
... WEDNESDAY, Oct. 5 (HealthDay News) -- A new oral drug ... rates and disability progression, according to the results of a ... one of the few oral drugs that treat this type ... for many MS patients, researchers said. "Basically, these ...
... Amanda Gardner HealthDay Reporter , WEDNESDAY, Oct. 5 ... listeria first linked to tainted cantaloupes has risen to 18, ... 20 states, the U.S. Centers for Disease Control and Prevention ... the cantaloupes in question were recalled Sept. 14, more cases ...
Cached Medicine News:Health News:Drug Combo Might Fight Aggressive Breast Cancer More Safely 2Health News:Drug Combo Might Fight Aggressive Breast Cancer More Safely 3Health News:MRI Safe With More Recent Defibrillators, Pacemakers: Study 2Health News:MRI Safe With More Recent Defibrillators, Pacemakers: Study 3Health News:Scientists Engineer Mice That Have Autism 2Health News:Scientists Engineer Mice That Have Autism 3Health News:Experimental MS Drug Shows Promise 2Health News:Experimental MS Drug Shows Promise 3Health News:18 Deaths From Cantaloupe-Linked Listeria Outbreak: CDC 2Health News:18 Deaths From Cantaloupe-Linked Listeria Outbreak: CDC 3
Inquire...
... work area that will help protect your ... irradiate the work area prior to use, ... be amplified. Containment features reduce the chance ... acrylic windows for a clear view, an ...
... x 24in(h). Designed to protect against ... The PCR Workstation irradiates the workspace prior ... airborne contamination by limiting exposure of experimental ... two fluorescent lights, one UV light, 12 ...
... Electropolished stainless steel ... mounts dampen vibration to ... as isolating vibration-producing equipment ... low-profile design allows for ...
Medicine Products: